CONTEXTVISION AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.86 NOK | -2.01% |
|
-4.56% | -23.90% |
| Apr. 03 | ContextVision Announces New Image Quality Advancements in X-Ray | CI |
| Feb. 16 | Transcript : ContextVision AB, Q4 2023 Earnings Call, Feb 16, 2024 |
| Sales 2024 * | 135M 12.13M | Sales 2025 * | 141M 12.67M | Capitalization | 453M 40.79M |
|---|---|---|---|---|---|
| Net income 2024 * | 18M 1.62M | Net income 2025 * | 20M 1.8M | EV / Sales 2024 * | 2.82 x |
| Net cash position 2024 * | 73.14M 6.58M | Net cash position 2025 * | 79.57M 7.16M | EV / Sales 2025 * | 2.65 x |
| P/E ratio 2024 * |
25.4
x | P/E ratio 2025 * |
22.4
x | Employees | 40 |
| Yield 2024 * |
3.43% | Yield 2025 * |
4.28% | Free-Float | 34.24% |
More Fundamentals
* Assessed data
More news
Latest transcript on ContextVision AB
More press releases
| 1 day | -2.01% | ||
| 1 week | -4.56% | ||
| Current month | -13.82% | ||
| 1 month | -13.82% | ||
| 3 months | -31.22% | ||
| 6 months | -19.73% | ||
| Current year | -23.90% |
1 week
5.84
6.18
1 month
5.846.98
Current year
5.849.20
1 year
5.849.82
3 years
5.8427.10
5 years
5.0530.90
10 years
1.4430.90
| Managers | Title | Age | Since |
|---|---|---|---|
Gerald Pötzsch
CEO | Chief Executive Officer | 52 | 22-07-31 |
| Director of Finance/CFO | - | 23-08-27 | |
Gunnar Läthén
CTO | Chief Tech/Sci/R&D Officer | - | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Martin Hedlund
FOU | Founder | 72 | 82-12-31 |
Lars Olof Sandèn
CHM | Chairman | 62 | 21-05-04 |
| Founder | 70 | 82-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 5.86 | -2.01% | 74,922 |
| 24-04-29 | 5.98 | +0.34% | 71,511 |
| 24-04-26 | 5.96 | -2.30% | 125,942 |
| 24-04-25 | 6.1 | -.--% | 2,211 |
| 24-04-24 | 6.1 | -.--% | 9,670 |
Real-time Oslo Bors, April 30, 2024 at 10:45 am EDT
More quotes
ContextVision AB is a Sweden-based medical technology software company specialized in image analysis and artificial intelligence. The Company is engaged in the image enhancement market and is a partner to the manufacturers of ultrasound, X-ray and Magnetic Resonance Imaging (MRI) equipment around the world. The Company develops software products, based on proprietary technology and artificial intelligence for image-based applications. ContextVisionâs cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment. The Company operates through two separate segments: the Business Unit Medical Imaging and the Business Unit Digital Pathology. ContextVision has two subsidiaries: Inify Laboratories AB og ContextVision Inc.
Calendar
2024-05-08
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
5.86
NOK
Average target price
6.5
NOK
Spread / Average Target
+10.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.90% | 42.08M | |
| +3.14% | 32.58B | |
| +16.26% | 7.65B | |
| +21.60% | 3.92B | |
| -16.02% | 3.19B | |
| -28.75% | 1.26B | |
| -31.01% | 1.14B | |
| -34.81% | 926M | |
| +1.34% | 908M | |
| -23.83% | 859M |
- Stock Market
- Equities
- CONTX Stock
